Literature DB >> 2186833

Theophylline in the management of airflow obstruction. 1. Much evidence suggests that theophylline is valuable.

G J Addis1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2186833      PMCID: PMC1662646          DOI: 10.1136/bmj.300.6729.928

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  18 in total

1.  Aminophylline in bronchial asthma.

Authors:  H A Rees; R C Borthwick; J S Millar; K W Donald
Journal:  Lancet       Date:  1967-12-02       Impact factor: 79.321

2.  A controlled trial of the use of single versus combined-drug therapy in the treatment of acute episodes of asthma.

Authors:  T H Rossing; C H Fanta; E R McFadden
Journal:  Am Rev Respir Dis       Date:  1981-02

3.  Sustained release oral aminophylline in patients with airflow obstruction.

Authors:  A P Greening; E Baillie; H R Gribbin; N B Pride
Journal:  Thorax       Date:  1981-04       Impact factor: 9.139

4.  Statistics and ethics in medical research: III How large a sample?

Authors:  D G Altman
Journal:  Br Med J       Date:  1980-11-15

5.  Theophylline serum concentration and therapeutic effect in severe acute bronchial obstruction: the optimal use of intravenously administered aminophylline.

Authors:  S Vozeh; G Kewitz; A Perruchoud; M Tschan; C Kopp; M Heitz; F Follath
Journal:  Am Rev Respir Dis       Date:  1982-02

6.  The influence of theophylline on maximal response to salbutamol in severe chronic obstructive pulmonary disease.

Authors:  J Barclay; B Whiting; G J Addis
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

7.  Dose response relation to oral theophylline in severe chronic obstructive airways disease.

Authors:  H Chrystyn; B A Mulley; M D Peake
Journal:  BMJ       Date:  1988-12-10

8.  Aminophylline, salbutamol and combined intravenous infusions in acute severe asthma.

Authors:  W V Evans; R D Monie; J Crimmins; A Seaton
Journal:  Br J Dis Chest       Date:  1980-10

9.  Theophylline-salbutamol interaction: bronchodilator response to salbutamol at maximally effective plasma theophylline concentrations.

Authors:  J Barclay; B Whiting; P A Meredith; G J Addis
Journal:  Br J Clin Pharmacol       Date:  1981-02       Impact factor: 4.335

10.  Effect of oral salbutamol and slow-release aminophylline on exercise tolerance in chronic bronchitis.

Authors:  A G Leitch; A Morgan; D A Ellis; G Bell; C Haslett; G J McHardy
Journal:  Thorax       Date:  1981-10       Impact factor: 9.139

View more
  7 in total

1.  A drug use review study in patients with obstructive lung disease. Assessment of the quality of drug therapy.

Authors:  G Van den Brink; C W Bollen; O E Van de Wall; L J Hoeve; A J Porsius
Journal:  Pharm Weekbl Sci       Date:  1992-10-16

2.  Asthma care in general practice--time for revolution?

Authors:  K Jones
Journal:  Br J Gen Pract       Date:  1991-06       Impact factor: 5.386

3.  Chronic respiratory failure in COPD: is there a place for a respiratory stimulant?

Authors:  P A Bardsley
Journal:  Thorax       Date:  1993-08       Impact factor: 9.139

4.  Intravenous aminophylline increases the degree of saturation of urine with calcium phosphate and struvite.

Authors:  A Siwińska; J Głuszek; J Maciejewski; D Musialik
Journal:  Int Urol Nephrol       Date:  1997       Impact factor: 2.370

5.  Value of theophylline treatment in patients handicapped by chronic obstructive lung disease.

Authors:  S E McKay; C A Howie; A H Thomson; B Whiting; G J Addis
Journal:  Thorax       Date:  1993-03       Impact factor: 9.139

6.  Effect of theophylline on exercise performance in patients with severe chronic obstructive pulmonary disease.

Authors:  G Fink; C Kaye; J Sulkes; U Gabbay; S A Spitzer
Journal:  Thorax       Date:  1994-04       Impact factor: 9.139

7.  Computer assisted design of a theophylline dosing regimen in acute bronchospasm: serum concentrations and clinical outcome.

Authors:  D Verner; H Seligmann; S Platt; S Dany; S Almog; L Zulty; H Halkin; D Ezra
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.